Categories: News

MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 11:45 am (ET). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.

Interested parties can access a link to the live webcast of the presentations from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations.  The webcast replay may be accessed at the same location for 14 days following the live presentation.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

Staff

Recent Posts

Dr. Airica Steed Shares Vision for Transforming Healthcare on the American Journal of Healthcare Strategy Podcast

Dr. Airica Steed Shares Vision for Transforming Healthcare on the American Journal of Healthcare Strategy…

3 hours ago

Laxxon Medical to Participate in 27th Annual Needham Growth Conference

NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Laxxon Medical, a leading pharma-technology…

3 hours ago

BioGene Therapeutics to Participate in the 43rd JP Morgan Healthcare Conference

Vancouver, British Columbia--(Newsfile Corp. - January 7, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

5 hours ago

Q2i Secures Patent for PARCA Solution, Revolutionizing Probation and Parole

BOSTON, Jan. 7, 2025 /PRNewswire/ -- Q2i, a leader in digital innovation, is proud to announce…

6 hours ago

McDermott Appoints Krist Werling to Lead Best-In-Class Global Health & Life Sciences Practice

CHICAGO, Jan. 7, 2025 /PRNewswire/ -- International law firm McDermott Will & Emery has appointed Kristian (Krist)…

6 hours ago

DeepScribe receives 98.8* overall performance score in KLAS Research report, with top grades in every category

The KLAS Emerging Company Spotlight includes 15 A+* grades for performance indicators across six categories, based…

6 hours ago